Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

Selection for an HIV-Resistant Immune System By Base-Edited CD45 CAR-T Cell Therapy

Nils Wellhausen, Yuqi Zhou, Michael S Bowman, Kusala Anupindi, Abhimanyu Gowda, Nils Engel, Carl H. June, Robert L. Bowman, James Riley, Saar Gill

Blood (2024) 144 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2024-206371

Published: 2024

Journal Articles

Engineering Myeloid Hematopoiesis By Nonviral Chimeric Antigen Receptor Knock-in to CD33 Enhances T Cell Infiltration in the Tumor Microenvironment

Nathan E Welty, Patrick Mellors, Olga Shestova, Darryl Sams, Om Gandhi, Joelle Kim, Xinhe Shan, Saar Gill

Blood (2024) 144 (Supplement 1): 85.

https://doi.org/10.1182/blood-2024-208014

Published: 2024

Journal Articles

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

Alison Carulli, Hayden Elliott, Brendan Mangan, James Whittenburg, Elise A. Chong, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, David L. Porter, Jordan S. Carter, Michael Roderick Cook, Nasheed Hossain, Saar Gill, Alfred L. Garfall, Christopher Catania, Colleen R. Kucharczuk, Stephen J. Schuster, Noelle Frey, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2024-203726

Published: 2024

Journal Articles

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Saamia Farooki, Han R Fisher, Anand S Bhagwat, Tina Glisovic-Aplenc, Lusha Cao, Regina M. Myers, Haley Newman, Caroline Diorio, Saar Gill, Richard Aplenc

Blood (2024) 144 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2024-201034

Published: 2024

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Blood (2024) 144 (Supplement 1): 499.

https://doi.org/10.1182/blood-2024-198249

Published: 2024

Journal Articles

CAR T Cells Accelerate Disease Progression in AMLs Harboring an Inflammatory Transcriptional Signature

Anand S Bhagwat, Maksim Shestov, Olga Shestova, Saar Gill

Blood (2024) 144 (Supplement 1): 2040.

https://doi.org/10.1182/blood-2024-207823

Published: 2024

Journal Articles

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Blood (2024) 144 (Supplement 1): 909.

https://doi.org/10.1182/blood-2024-202659

Published: 2024

Journal Articles

Single Cell Transcriptomics of Bronchiolitis Obliterans Syndrome

Patrick Mellors, Ana Nottingham, Maksim Shestov, Maria Basil, Saar Gill

Blood (2023) 142 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2023-180062

Published: 2023

Journal Articles

Molecular Attributes of CAR T Cell Fitness in Patients with Chronic Lymphocytic Leukemia

Xiaoli Mi, Dennis Yuan, Rebecca Murray, Jani Huuhtanen, Beatrice Zhang, Jean Quentin, Olga Shestova, David L. Porter, Satu Mustjoki, Saar Gill, Dan A. Landau

Blood (2023) 142 (Supplement 1): 3452.

https://doi.org/10.1182/blood-2023-187956

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Blood (2023) 142 (Supplement 1): 955.

https://doi.org/10.1182/blood-2023-180185

Published: 2023

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Matthew P Connor, Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok

Blood (2023) 142 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2023-179383

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Ashley D Hadjis, Griffin W White, Christopher Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Andrew H Matthews, Mary Ellen Martin, Daria V Babushok, Alexander Perl, David L. Porter, Alison W Loren, Keith W Pratz, Selina M Luger, Shannon R McCurdy

Blood (2023) 142 (Supplement 1): 376.

https://doi.org/10.1182/blood-2023-188978

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Blood (2022) 140 (Supplement 1): 10542–10544.

https://doi.org/10.1182/blood-2022-167098

Published: 2022

Journal Articles

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

David A. Sallman, Daniel J. DeAngelo, Naveen Pemmaraju, Shira Dinner, Saar Gill, Rebecca L. Olin, Eunice S. Wang, Marina Konopleva, Eileen Stark, Ana Korngold, Asifa Haider, Kate Backhouse, Carolyn Figliola, Daniel J. Lee, Mark G. Frattini, Carrie Brownstein, Gail J. Roboz

Blood (2022) 140 (Supplement 1): 2371–2373.

https://doi.org/10.1182/blood-2022-169928

Published: 2022

Journal Articles

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Caroline Diorio, Tiffaney L. Vincent, Tori Fuller, Rawan Shraim, Tina Glisovic-Aplenc, Theresa Ryan, Kimberly Veliz, Haley Newman, Gerald Wertheim, Hamid Bassiri, Annette Vu, Michael Hogarty, Carl H June, Stephan A. Grupp, Sarah K Tasian, Richard Aplenc, Saar Gill, David T. Teachey

Blood (2022) 140 (Supplement 1): 10285–10286.

https://doi.org/10.1182/blood-2022-167893

Published: 2022

NARROW

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Selection for an HIV-Resistant Immune System By Base-Edited CD45 CAR-T Cell Therapy

Engineering Myeloid Hematopoiesis By Nonviral Chimeric Antigen Receptor Knock-in to CD33 Enhances T Cell Infiltration in the Tumor Microenvironment

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

CAR T Cells Accelerate Disease Progression in AMLs Harboring an Inflammatory Transcriptional Signature

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Single Cell Transcriptomics of Bronchiolitis Obliterans Syndrome

Molecular Attributes of CAR T Cell Fitness in Patients with Chronic Lymphocytic Leukemia

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only